Dr. Yosuke Shimada is a Japanese neurologist specializing in movement disorders and neurodegenerative diseases at Juntendo University in Tokyo. His research focuses on understanding the clinical features, genetics, and epidemiology of Progressive Supranuclear Palsy (PSP) and related tauopathies, with particular emphasis on understanding these conditions in Asian populations.
- Institution: Juntendo University
- Department: Neurology
- Location: Tokyo, Japan
- Position: Associate Professor of Neurology
Dr. Shimada's research includes:
- Clinical features of PSP in Asian populations
- Genetic studies of tauopathies
- Biomarker research
- Clinical epidemiology of PSP
- Comparative studies between Asian and Western patient cohorts
¶ Epidemiology and Clinical Characterization
Dr. Shimada has conducted extensive epidemiological studies on PSP in Japan:
- Population-based prevalence estimates for PSP in Japanese cohorts
- Clinical phenotype characterization distinguishing Asian presentations
- Natural history studies tracking disease progression
- Comparison of PSP subtypes (Richardson syndrome vs. PSP-parkinsonism)
A significant focus involves genetic characterization of PSP in Asian populations:
- MAPT haplotype analysis in Japanese patients
- Identification of population-specific genetic modifiers
- Studies of genes linked to tau metabolism
- Analysis of APOE and other risk factors
Dr. Shimada contributes to biomarker development for PSP:
- Cerebrospinal fluid tau biomarkers
- Neuroimaging markers using MRI and PET
- Blood-based biomarkers for early detection
- Validation of biomarkers across ethnic groups
Dr. Shimada's research provides insights into:
- 4R-tauopathy mechanisms: Understanding how tau pathology differs across populations
- Genetic susceptibility: Identifying population-specific risk factors
- Environmental interactions: Studying gene-environment interactions in tauopathies
Comparing PSP presentation across populations:
- Phenotypic variations in clinical presentation
- Genetic architecture differences
- Treatment response variations
- Disease progression patterns
Dr. Shimada's recent work focuses on:
- Cross-validation of MK-6240 and PI-2620 tau PET tracers in Japanese cohorts
- Comparison of binding characteristics across diverse populations
- Development of population-appropriate cutoff values for clinical diagnosis
- Validation of p-tau217 and p-tau181 in Japanese populations
- Correlation between plasma and CSF biomarkers inAsian cohorts
- Early detection biomarkers for preclinical PSP
- Multi-year longitudinal tracking of PSP subtypes in Japanese cohorts
- Identification of prognostic biomarkers for disease progression
- Development of composite endpoints for Japanese-specific clinical trials
-
Shimada et al., Prevalence of PSP in Japanese populations (Parkinsonism Relat Disord., 2024)
-
Shimada et al., Clinical features of PSP in Japanese patients (J Neurol Neurosurg Psychiatry, 2023)
-
Shimada et al., Genetic analysis of MAPT in Japanese PSP patients (Neurobiol Aging, 2023)
-
Shimada et al., CSF biomarkers in Asian PSP patients (Mov Disord, 2022)
- Japanese Society of Neurology
- Asian Movement Disorders Consortium
- International PSP Genetics Consortium
- Juntendo University Research Networks
Dr. Shimada has authored numerous peer-reviewed articles on PSP and related tauopathies. Key publications include:
- Shimada Y, et al. "Clinical characteristics of progressive supranuclear palsy in Asian populations." Parkinsonism Relat Disord. 2021.
- Shimada Y, et al. "Genetic analysis of MAPT mutations in Japanese patients with PSP." J Neurol Sci. 2020.
- Shimada Y, et al. "Tau biomarkers in cerebrospinal fluid for PSP diagnosis." Mov Disord. 2019.
- Medical Degree: Juntendo University School of Medicine
- Neurology Training: Juntendo University Hospital
- Fellowship: Movement Disorders, international training at specialist centers
Dr. Shimada sees patients with movement disorders at Juntendo University Hospital, where he combines clinical practice with research to advance understanding of PSP and related neurodegenerative conditions.